Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Myeloid 2

Conditions

Breast Neoplasms 138Neoplasms 118Prostatic Neoplasms 64Lung Neoplasms 48Head and Neck Neoplasms 46Colorectal Neoplasms 38Ovarian Neoplasms 33Uterine Cervical Neoplasms 29Endometrial Neoplasms 23Motor Activity 22Neoplasm Metastasis 20Multiple Myeloma 20Pancreatic Neoplasms 19Brain Neoplasms 19Rectal Neoplasms 18Lymphoma 17Colonic Neoplasms 17Pain 16Gastrointestinal Neoplasms 16Fatigue 16Carcinoma, Non-Small-Cell Lung 16Leukemia 15Depression 15Oropharyngeal Neoplasms 13Melanoma 13Anxiety Disorders 13Urinary Bladder Neoplasms 12Hematologic Neoplasms 12Esophageal Neoplasms 12Stomach Neoplasms 11

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Biopsy 15Flow Cytometry 14Cyclosporins 14Alemtuzumab 14thymoglobulin 13venetoclax 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Surveys and Questionnaires × Clear all
NCT04378855 2025-09-23

PROPHECY

Gruppo Italiano Malattie EMatologiche dell'Adulto

Active not recruiting
572 enrolled
Myeloid

Myeloproliferative Disorders

NCT02410551 2018-10-30

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled 5 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡